Low-energy ultrasound treatment improves regional tumor vessel infarction by retargeted tissue factor

Journal of Ultrasound in Medicine

Volumn 34, Issue 7, 2015, Pages 1227-1236

  Brand, Caroline ^a   Dencks, Stefanie ^b   Schmitz, Georg ^b   Mühlmeister, Mareike ^c   Stypmann, Jörg ^a   Ross, Rebecca ^a   Hintelmann, Heike ^a   Schliemann, Christoph ^a   Müller Tidow, Carsten ^a   Mesters, Rolf M ^a   Berdel, Wolfgang E ^a   Schwöppe, Christian ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Low energy ultrasound treatment; Regional cancer therapy; Truncated tissue factor; Vascular infarction; Vascular targeting; Vascular ultrasound

Indexed keywords

CELL MEMBRANES; CELLS; COAGULATION; CYTOLOGY; LIPID BILAYERS; MAMMALS; TISSUE; TUMORS; ULTRASONICS;

CANCER THERAPY; TISSUE FACTORS; ULTRASOUND TREATMENTS; VASCULAR INFARCTION; VASCULAR TARGETING; VASCULAR ULTRASOUND;

ENDOTHELIAL CELLS;

ANGIOGENESIS INHIBITOR; THROMBOPLASTIN;

ANIMAL; DISEASE MODEL; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; HUMAN; INFARCTION; MICROBUBBLE; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; TUMOR CELL LINE; ULTRASOUND THERAPY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; HUMANS; INFARCTION; MICE; MICE, NUDE; MICROBUBBLES; NEOVASCULARIZATION, PATHOLOGIC; THROMBOPLASTIN; ULTRASONIC THERAPY;

EID: 84933512627     PISSN: 02784297     EISSN: 15509613     Source Type: Journal    
DOI: 10.7863/ultra.34.7.1227     Document Type: Article

References (67)

1. Schlag PM, Stein U. Regional cancer therapy. In: Teicher B (ed). Cancer Drug Discovery and Development. Totowa, NJ: Humana Press; 2010:1-455.
2. Folkman J. Angiogenesis in cancer, vascular, reumatoid and other disease. Nat Med 1995; 1:27-31.
3. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5:1359-1364.
4. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010; 10:505-514.
5. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis [published erratum appears in Nat Rev Clin Oncol 2011; 8:316]. Nat Rev Clin Oncol 2011; 8:210-221.
6. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5:423-435.
7. Chaplin DJ, Dougherty GJ, Siemann DW. Vascular disrupting agents. In: Davis DW, Herbst R, Abbruzzese JL (eds). Antiangiogenic Cancer Therapy. Boca Raton, FL: CRC Press; 2008:329-364.
8. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982; 45:136-139.
9. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5:436-446.
10. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha V beta 3 for angiogenesis. Science 1994; 264:569-571.
11. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology 1995; 13:265-270.
12. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci USA 1997; 94:13612-13617.
13. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60:722-727.
14. Guzman-Rojas L, Rangel R, Salameh A, et al. Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci USA 2012; 109:1637-1642.
15. Curnis F, Arrigoni G, Sacchi A, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002; 62:867-874.
16. Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood 2008; 112:2628-2635.
17. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279:377-380.
18. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5:1032-1038.
19. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296:2404-2407.
20. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 2000; 10:435-442.
21. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275:547-550.
22. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81:734-744.
23. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001; 61:711-716.
24. Liu C, Huang H, Donate F, et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 2002; 62:5470-5475.
25. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998; 58:4646-4653.
26. Kessler T, Bieker R, Padró T, et al. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res 2005; 11:6317-6324.
27. Dienst A, Grunow A, Unruh M, et al. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 2005; 97:733-747.
28. Kessler T, Schwöppe C, Liersch R, et al. Generation of fusion proteins for selective occlusion of tumor vessels. Curr Drug Discov Technol 2008; 5:1-8.
29. Bieker R, Kessler T, Schwöppe C, et al. Infarction of tumor vessels by NGR-peptide directed targeting of tissue factor: experimental results and first-in-man experience. Blood 2009; 113:5019-5027.
30. Schwöppe C, Kessler T, Persigehl T, et al. Tissue-factor fusion proteins induce occlusion of tumor vessels. Thromb Res 2010; 125(suppl 2):S143-S150.
31. Persigehl T, Ring J, Bremer C, et al. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging. Angiogenesis 2014; 17:235-246
32. Dreischalück J, Schwöppe C, Spieker T, et al. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile. Int J Oncol 2010; 37:1389-1397.
33. Schwöppe C, Zerbst C, Fröhlich M, et al. Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated tissue factor. J Med Chem 2013; 56:2337-2347.
34. Seip R, Chin CT, Hall CS, Raju BI, Ghanem A, Tiemann K. Targeted ultrasound mediated delivery of nanoparticles: on the development of a new HIFU-based therapy and imaging device. IEEE Trans Biomed Eng 2010; 57:61-70.
35. Greis C. Technology overview: SonoVue. Eur Radiol 2004; 14(suppl 8):P11-P15.
36. Vos HJ, Emmer M, de Jong N. Oscillation of single microbubbles at room versus body temperature. In: IEEE Ultrasonics Symposium. Piscataway, NJ: Institute of Electrical and Electronics Engineers; 2008:982-984.
37. Sun S, Sboros V, Butler MB, Moran CM. In vitro acoustic characterization of three phospholipid ultrasound contrast agents from 12 to 43 MHz. Ultrasound Med Biol 2014; 40:541-550.
38. Schellenberger, EA. Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy. Neoplasia 2003; 5:187-192.
39. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function [published erratum appears in J Biol Chem 1991; 266:16256]. J Biol Chem 1991; 266:2158-2166.
40. Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86:1062-1071.
41. Daigeler A, Chromik AM, Haendschke K, et al. Synergistic effects of sonoporation and taurolidin/trail on apoptosis in human fibrosarcoma. Ultrasound Med Biol 2010; 36:1893-1906.
42. Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol 2010; 58:803-815.
43. Liu Y, Kon T, Li C, Zhong P. High intensity focused ultrasound-induced gene activation in sublethally injured tumor cells in vitro. J Acoust Soc Am 2006; 118:3328-3336.
44. Guo Q, Jiang LX, Hu B. Cell apoptosis and proliferation inhibition of pancreatic cancer induced by sub-threshold focused ultrasound (FUS). Eur J Radiol 2012; 81:e704-e707.
45. Hundt W, O'Connell-Rodwell CE, Bednarski MD, Steinbach S, Guccione S. In vitro effect of focused ultrasound or thermal stress on HSP70 expression and cell viability in three tumor cell lines. Acad Radiol 2007; 14:859-870.
46. Delalande A, Kotopoulis S, Postema M, Midoux P, Pichon C. Sonoporation: mechanistic insights and ongoing challenges for gene transfer. Gene 2013; 525:191-199.
47. Hensel K, Mienkina MP, Schmitz G. Analysis of ultrasound fields in cell culture wells for in vitro ultrasound therapy experiments. Ultrasound Med Biol 2011; 37:2105-2115.
48. Alexander A, Dwivedi S, Ajazuddin, et al. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release 2012; 164: 26-40.
49. Feril LB Jr, Kondo T, Cui ZG, et al. Apoptosis induced by the sonomechanical effects of low intensity pulsed ultrasound in a human leukemia cell line. Cancer Lett 2005; 221:145-152.
50. Dörner J, Struck R, Zimmer S, et al. Ultrasound-mediated stimulation of microbubbles after acute myocardial infarction and reperfusion ameliorates left-ventricular remodelling in mice via improvement of borderzone vascularization. PLoS One 2013; 8:e56841.
51. Banner DW, D'Arcy A, Chène C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380:41-46.
52. Thorpe PE. Targeting anionic phospholipids on tumor blood vessels and tumor cells. Thromb Res 2010; 125(suppl 2):S134-S137.
53. Ran S, Thorpe P. Phosphatidyserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002; 54:1479-1484.
54. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002; 62:6132-6140.
55. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89:2429-2442.
56. von Maltzahn G, Park JH, Lin KY, et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater 2011; 10:545-552.
57. Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25:4007-4020.
58. Wood AK, Ansaloni S, Ziemer LS, Lee WM, Feldman MD, Sehgal CM. The antivascular action of physiotherapy ultrasound on murine tumors. Ultrasound Med Biol 2005; 31:1403-1410.
59. Wood AK, Bunte RM, Cohen JD, Tsai JH, Lee WM, Sehgal CM. The antivascular action of physiotherapy ultrasound on a murine tumor: role of a microbubble contrast agent. Ultrasound Med Biol 2007; 33:1901-1910.
60. Wood AK, Bunte RM, Price HE, et al. The disruption of murine tumor neovasculature by low-intensity ultrasound: comparison between 1- and 3-MHz sonication frequencies. Acad Radiol 2008; 15:1133-1141.
61. Goertz DE, Karshafian R, Hynynen K. Investigating the effects of pulsed low Intensity ultrasound and microbubbles in mouse tumors. In: IEEE Ultrasonics Symposium. Piscataway, NJ: Institute of Electrical and Electronics Engineers; 2009:89-92.
62. Al-Mahrouki AA, Karshafian R, Giles A, Czarnota GJ. Bioeffects of ultrasound-stimulated microbubbles on endothelial cells: gene expression changes associated with radiation enhancement in vitro. Ultrasound Med Biol 2012; 38:1958-1969.
63. Wu J, Nyborg WL. Ultrasound, cavitation bubbles and their interaction with cells. Adv Drug Deliv Rev 2008; 60:1103-1116.
64. Ohl CD, Arora M, Ikink R, et al. Sonoporation from jetting cavitation bubbles. Biophys J 2006; 91:4285-4295.
65. Czarnota GJ, Karshafian R, Burns PN, et al. Tumor radiation response enhancement by acoustical stimulation of the vasculature. Proc Natl Acad Sci USA 2012; 109:E2033-E2041.
66. Hassan MA, Feril LB, Suzuki K, Kudo N, Tachibana K, Kondo T. Evaluation and comparison of three novel microbubbles: enhancement of ultrasound-induced cell death and free radicals production. Ultrason Sonochem 2009; 16:372-378.
67. Spronk HMH, ten Cate H, van der Meijden PEJ. Differential roles of tissue factor and phosphatidylserine in activation of coagulation. Thromb Res 2014; 133(suppl 1):S54-S56.